Walder Wyss advised Fielmann Group and tele-ophthalmology platform Ocumeda, as the the first agreed to sell a 10% stake in Ocumenda to Zeiss Vision Care. The deal implied a total company valuation of EUR 100m, with
Tags :Slider
Lenz & Staehelin advised private equity healthcare specialist Archimed on its acquisition of a majority stake in family-owned ExcellGene and sister company Magellan Biologics & Consulting, both active in the biologic therapeutics sector. The deal
Lenz & Staehelin advised Prof. Dr. Martin Janssen in connection with the sale of Ecofin Investment Consulting – a company founded by Janssen himslef – to the Vaudoise Group. The company Headquartered in Zurich, Ecofin Investment Consulting
Landis+Gyr divested its EMEA business to private equity investor Aurelius, for an enterprise value of USD 215 m. The divestment encompasses five production sites across EMEA and involves a workforce of approximately 2,700 employees. In connection
Niederer Kraft Frey (NKF) advised SpineArt, as the Swiss medtech specialist raised CHF 25 million in a capital increase backed by investors Gimv and EGS Beteiligungen (EGSB). In connection with the operation, Bär & Karrer
Niederer Kraft Frey (NKF) advised German software investor Maguar Capital on its acquisition of Signagelive, a UK-based CMS softwares specialist. Navori Labs – a Maguar portfolio company with headquarters in Lausanne- worked through the acquisition in
SMG – a joint venture between TX Group, Ringier, Mobiliar and General Atlantic – makes its debut today, September 19, on the SIX Swiss Exchange. The Zurich-based group trades under the ticker symbol “SMG”, pricing at CHF 46 per
Walder Wyss advised Helvetia Schweizerische Versicherungsgesellschaft and Helvetia Holding on a new CHF 300m syndicated revolving credit facility. Moreover – in connection with the deal – Niederer Kraft Frey (NKF) represented Deutsche Bank AG as coordinator and
Wenger Vieli advised the shareholders of Swiss-based individualised rehabilitation specialist SKS Rehab in connection with its merger with Roltec El-Kørestole, leading to the formation of the new SKS Roltec Group. Moreover, the SKS Roltec
Japanese Morimatsu Group completed the acquisition of Swiss bioreactors specialist Bioengineering. In connection with the deal Niederer Kraft Frey (NKF) advised the former owners Bioengineering, while Schellenberg Wittmer advised the buyer. The parties Morimatsu is
